KIDS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -6.31%, SMA50 -6.72%, SMA200 -14.16%). The stock’s 14-day RSI is 37.65 (weak momentum), while the ATR of 0.73 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -36.7% below its high and over 9.36% above its low. Average 10-day trading volume of 114.33 thousand shares is below the 3-month average of 169.64 thousand, indicating normal recent market interest.

OrthoPediatrics Corp. has 25.07 million shares outstanding. The public float is 16.88 million shares, elevated short interest at 6.86% of float. This equals 1.16 million shares. The short ratio is 8.09 days. Institutional investors hold 105.96% of the float. Insiders own 32.71%. Pelizzon David R holds 1.52 million shares, Squadron Capital LLC has 1.52 million shares and Squadron Capital Holdings LLC has 1.52 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

OrthoPediatrics Corp. generated EPS of -$1.96 over the past year. Five-year average earnings growth is -11.79%. Wall Street analysts project EPS growth of 9.22% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.29. Next year's EPS is expected at $5.09. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $20.00. The high target offers 199.22% upside. The low target suggests 19.69% downside. The mean target is $31.06. This offers 85.88% upside. OrthoPediatrics Corp. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -7.69%. The prior quarter beat by -35.29%. Over the last six quarters, Apple has recorded several small beats. These include -25.81% in August 05, 2024.

OrthoPediatrics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $43.34. This means the shares are trading below this model’s fair value.

OrthoPediatrics Corp. (NASDAQ:KIDS) shares are flat 3.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OrthoPediatrics Corp. trading at a premium to the broader market with a P/E of -8.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $41.13, suggesting 146.14% upside. Our AI forecast model points to short-term weakness (-9.63% over two weeks), a medium-term fall (-25.19% over three months), and a longer-term loss (-64.69% over one year), with expected trading ranges indicating moderate volatility.

OrthoPediatrics Corp. (NASDAQ:KIDS) closed at $16.71 USD, gaining $0.06 (0.36%) from the previous close of $16.65. The stock is currently mid-range between its 52-week high and low $15.28 and $26.40. With a market capitalization of about $419.04 million, OrthoPediatrics Corp. is classified as a small-cap and shows market-like volatility (beta ~1.10). Key stats such as the average daily volume over the past year has been around 174.81 thousand shares, in line with its 52-week average. Headquartered in Warsaw, IN, OrthoPediatrics Corp. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO David R. Bailey, the company employs approximately 562 people and listed since October 13, 2017. OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally.

Our AI price prediction model suggests that OrthoPediatrics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.63%, with price expected at $15.10 by February 20, 2026, within a range of $14.67 to $15.53 3-Month Outlook: Projected fall of -25.19%, reaching $12.50 by May 07, 2026, with a range of $11.73 to $13.15. 1-Year Outlook: Projected loss of -64.69%, with price at $5.90 by February 05, 2027, within a range of $4.50 to $7.30.

OrthoPediatrics Corp. trades at a P/E ratio of -8.58, slightly below the S&P 500 average, with a price-to-sales ratio of 1.84 and a price-to-book ratio of 1.12 suggesting the stock is closer to book value. The P/FCF stands at -14.24, also below market averages.